Keyphrases
Graft-versus-host Disease (GvHD)
100%
Non-relapse Mortality
45%
Mount Sinai
42%
International Consortium
40%
Clinical Trials
19%
High Risk
16%
Risk Stratification
13%
Disease Risk
13%
Hematopoietic Cell Transplantation
12%
Steroid-refractory Graft-versus-host Disease
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Low Risk
9%
Disease Biomarker
9%
Ruxolitinib
8%
Corticosteroid Treatment
8%
Day 14
8%
Treatment Response
7%
Prognostic Biomarker
7%
Soluble Suppression of Tumorigenicity 2 (sST2)
7%
Risk Biomarkers
7%
TNF Receptor 1 (TNFR1)
6%
Pediatric Patients
6%
Injury Biomarkers
6%
Natalizumab
6%
Targeted Therapy
6%
Phase II Study
6%
Hematopoietic Cell Transplant
6%
Steroid Resistance
6%
Tissue Damage
6%
Itacitinib
6%
Thyroid Cancer
6%
Risk Factors
6%
Corticosteroids
6%
Relapse Risk
6%
Clinical Presentation
6%
Late Acute
6%
Biomarkers of Response
6%
Elafin
6%
Gastrointestinal Tissues
6%
Risk Outcomes
6%
Infectious Diseases
6%
Marrow Transplantation
6%
Technical Committee
6%
Cell Therapy
6%
Clinical Trials Network
6%
Second-line Therapy
6%
Antitrypsin
6%
Preemption
6%
Emicizumab
6%
Hemophilia
6%
Immunology and Microbiology
Graft-Versus-Host Disease
92%
Acute Graft Versus Host Disease
87%
Hematopoietic Cell
21%
Transplant Procedure
11%
Cell Transplantation
11%
Overall Survival
8%
Prognostic Biomarker
7%
Gastrointestinal Tissue
6%
Natalizumab
6%
Elafin
6%
Amphiregulin
6%
Immunosuppression
5%
Medicine and Dentistry
Acute Graft Versus Host Disease
41%
Biological Marker
36%
Graft Versus Host Reaction
35%
Cell Transplantation
10%
Hematopoietic Stem Cell
10%
Clinical Trial
9%
Risk Stratification
6%
Pediatrics Patient
6%
Carcinogenicity
6%
Amphiregulin
6%
Thyroid Cancer
6%
Infection
6%
Treatment Response
6%
Ruxolitinib
6%
Systemic Therapy
5%
Malignant Neoplasm
5%
